Skip to main content

Molecular and Cellular Probes

  • ISSN: 0890-8508

Editor-In-Chief: Nagy

Next planned ship date: May 21, 2024

  • 5 Year impact factor: 2.8
  • Impact factor: 3.3

MCP—Advancing Biology and Medicine through Omics and Bioinformatic Technologies wants to capture outcomes from the current revolution in molecular technologies and sciences… Read more

Subscription options

Next planned ship date:
May 21, 2024

Institutional subscription on ScienceDirect

Request a sales quote
MCP—Advancing Biology and Medicine through Omics and Bioinformatic Technologies wants to capture outcomes from the current revolution in molecular technologies and sciences. The journal has broadened its scope and embraces any high-quality research papers and reviews in areas including, but not limited to, molecular biology; cell biology; biochemistry; molecular physiology; genetics; evolutionary biology; genomics (including metagenomics); proteomics; metabolomics; glycomics and lipidomics, cancer; hematology and oncohematology; medical and veterinary epidemiology; immunology; virology; microbiology; vaccinology; molecular diagnostics of non-infectious, infectious, and parasitic diseases; and animal models in biomedical research. Submissions with a technology-driven focus on understanding normal biological or disease development processes, as well as conceptual advances and paradigm shifts, are particularly encouraged. We especially welcome works related to the revolutionary application of liquid biopsy and metagenomic next-generation sequencing in the detection of different diseases and follow-up to patients' treatment regimens by using exosomes and cell-free nucleic acids (DNA, mtDNA, mRNA, microRNA, long non-coding RNA, circular RNA, etc.). Studies on extracellular nucleic acids in normal and pathological condition and the treatment of diseases are the focus of MCP. Pure clinical studies and hypothesis-driven research are also suitable (e.g., clinical application of metabolomics/proteomics/transcriptomics using human samples). Only bioinformatic works with proven experimental confirmation will be accepted.

Top quality research and manuscripts will be fast-tracked. A highly cited international editorial board assures timely publication of manuscripts.

Review articles

In general, review articles submitted to our journal should be done by invitation of the Editor-in-Chief (EIC). Please send your concept, with an abstract, to the EIC to start the discussion.

Benefits to authors

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications, and much more. For more information, please see our Author Tools and Resources page.



Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center.